Eisenmenger Complex – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033


 

Eisenmenger Complex is a clinical syndrome resulting from a congenital heart defect characterized by large anatomical shunts. Hemodynamic forces acting on these anatomic abnormalities initially cause a left-to-right shunt, leading to the development of severe pulmonary arterial hypertension (PAH) and increased vascular resistance. Eventually, due to elevated pulmonary vascular resistance, the direction of the shunt reverses, resulting in a right-to-left shunt and subsequent hypoxemia and cyanosis. Eisenmenger syndrome can arise from various heart defects that induce PAH, including atrial septal defects (ASD), ventricular septal defects (VSD), atrioventricular septal defects (AVSD), and patent ductus arteriosus (PDA), as well as more complex cardiac lesions. Unrepaired Tetralogy of Fallot (ToF) can also lead to the development of Eisenmenger syndrome. The most frequently observed defects associated with Eisenmenger syndrome are ASD, VSD, and PDA. The transformation of a left-to-right shunt into a right-to-left shunt involves three primary processes: vasoconstriction due to imbalances in pulmonary vascular tone, vascular remodeling resulting from the proliferation of pulmonary vascular smooth muscle, and thrombosis caused by increased blood flow resistance. The common clinical manifestations of Eisenmenger syndrome include angina (chest pain), arrhythmias (abnormal heartbeat), clubbing (abnormal enlargement and curvature of fingernails and toenails), hemoptysis (coughing up blood), and cyanosis. Individuals with Eisenmenger syndrome have reduced life expectancy, with high mortality rates occurring in the third and fourth decades of life. Ventricular failure, hemoptysis, complications during pregnancy, and strokes are common causes of death. Treatment for Eisenmenger syndrome aims to alleviate symptoms and prevent severe damage to the heart and lungs. Therapeutic approaches may include antibiotics, anticoagulants, diuretics, dual endothelin receptor antagonists, iron supplements, and supplemental oxygen.

  • Approximately 1% to 6% of adults with congenital heart defects develop Eisenmenger syndrome.

Thelansis’s “Eisenmenger Complex Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Eisenmenger Complex treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Eisenmenger Complex across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Eisenmenger Complex Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Eisenmenger Complex – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Comments

Post a Comment

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Image
  Acne vulgaris, a prevalent pilosebaceous unit inflammatory skin disorder, follows a persistent course. Typically presenting as papules, pustules, or nodules, it primarily occurs on the face but can also impact the upper arms, trunk, and back. The development of acne results from the sebaceous glands' heightened sensitivity to normal androgen levels, aggravated by Cutibacterium acnes (formerly known as Propionibacterium acnes), a bacterial species that triggers inflammation. The pathogenesis of acne vulgaris involves a complex interplay of factors such as the activation of sebaceous glands by androgens, imbalances in the pilosebaceous follicle microbiome, and cellular immune responses. Genetic predisposition and dietary influences also contribute to the condition's onset and progression. The initial stage is the micro-comedo, a small plug primarily composed of corneocytes in the lower follicular infundibulum. Microcomedones evolve into various acne lesions, including closed co...
Read more

Herpes Simplex Virus (HSV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
 Herpes simplex virus (HSV) causes an infection that affects the external genitalia, anal region, mucosal surfaces, and skin in other body parts. Herpes simplex virus is a ubiquitous, host-adapted pathogen that causes various disease states. There are two types of HSV with two distinct DNA viruses, type 1 (HSV-1) and type 2 (HSV-2). Both the types are closely related but differ epidemiologically. HSV-1 is traditionally associated with orofacial disease by affecting the mouth and lips with fever blisters and cold sores, whereas HSV-2 is associated traditionally with genital disease infecting genitals and rectum area with sores and is classified as STD (sexually transmitted disease). As HSV-1 is associated with genital infections more often than HSV-2, lesion location is not necessarily of viral type. HSV can spread through direct contact. Almost 80% of Herpes simplex infections are asymptomatic, while symptomatic infections can be characterized by significant morbidity and recurrenc...
Read more

HR+/HER2- Breast Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
Thelansis’s “HR+/HER2- Breast Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential HR+/HER2- Breast Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). KOLs insights of HR+/HER2- Breast Cancer across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs. HR+/HER2- Breast Cancer Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model,...
Read more